[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0417947A - composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica - Google Patents

composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica

Info

Publication number
BRPI0417947A
BRPI0417947A BRPI0417947-1A BRPI0417947A BRPI0417947A BR PI0417947 A BRPI0417947 A BR PI0417947A BR PI0417947 A BRPI0417947 A BR PI0417947A BR PI0417947 A BRPI0417947 A BR PI0417947A
Authority
BR
Brazil
Prior art keywords
prevention
manufacture
compound
treatment
medicament
Prior art date
Application number
BRPI0417947-1A
Other languages
English (en)
Inventor
Nathan Bryan Mantlo
Antonio Navarro
Ashraf Saeed
Douglas Linn Gernert
Tianwei Ma
Lance Allen Pfeifer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0417947A publication Critical patent/BRPI0417947A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, FABRICAçãO DE UM MEDICAMENTO PARA O USO NO TRATAMENTO E/OU PREVENçãO DE UM METABóLICO DISTúRBIO, E, FORMULAçãO FARMACêUTICA". A presente invenção está direcionada aos compostos representados pela seguinte fórmula estrutural, Fórmula (I): em que: (a) X é selecionado do grupo que consiste de uma ligação simples, O e S; (b) U é um ligador alifático; (c) Y é selecionado do grupo que consiste de O, C e S; (d) W é N; (e) E é C(R3)(R4)A; (f) R3 e R4 são cada um metila; (g) A é carboxila.
BRPI0417947-1A 2003-12-22 2004-12-21 composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica BRPI0417947A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53232003P 2003-12-22 2003-12-22
US58656304P 2004-07-09 2004-07-09
EP04380159 2004-07-21
EP04380158 2004-07-21
PCT/US2004/039775 WO2005065683A1 (en) 2003-12-22 2004-12-21 Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes

Publications (1)

Publication Number Publication Date
BRPI0417947A true BRPI0417947A (pt) 2007-04-17

Family

ID=34753767

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417947-1A BRPI0417947A (pt) 2003-12-22 2004-12-21 composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica

Country Status (8)

Country Link
US (1) US7507832B2 (pt)
EP (1) EP1725231A1 (pt)
JP (1) JP2007515484A (pt)
CN (1) CN1909902A (pt)
AU (1) AU2004311909A1 (pt)
BR (1) BRPI0417947A (pt)
CA (1) CA2549385A1 (pt)
WO (1) WO2005065683A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
JP2007284352A (ja) * 2004-08-05 2007-11-01 Dai Ichi Seiyaku Co Ltd ピラゾール誘導体
CA2580409C (en) 2004-09-16 2013-08-13 Astellas Pharma Inc. Triazole derivative or salt thereof
CA2595789A1 (en) * 2005-02-03 2006-08-10 Irm Llc Compounds and compositions as ppar modulators
WO2007039171A1 (en) * 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
TW200812982A (en) * 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR
JP5119241B2 (ja) 2006-05-24 2013-01-16 イーライ リリー アンド カンパニー Ｆｘｒアゴニスト
DE602007011446D1 (en) * 2006-05-30 2011-02-03 Astrazeneca Ab Substituierte 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a-diacylglycerolacyltransferase
BRPI0712796A2 (pt) * 2006-05-30 2012-10-02 Astrazeneca Ab composto, métodos para produzir uma inibição da atividade de dgat1 em um animal de sangue quente, para tratar a diabete melito e/ou a obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para um composto
EP2234954B1 (en) 2007-12-20 2015-02-18 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
BRPI0914121B8 (pt) * 2008-07-03 2021-05-25 Astellas Pharma Inc derivado de triazol ou sal do mesmo
JP2010018531A (ja) * 2008-07-09 2010-01-28 Sumitomo Seika Chem Co Ltd ３−ベンジルオキシベンゼンチオールの製造方法
BRPI0920237A2 (pt) * 2008-10-21 2015-12-29 Metabolex Inc agonistas do receptor aril gpr120 e suas respectivas utilizações
BRPI1007414A2 (pt) * 2009-01-28 2018-03-06 Sanofi derivados de tiadiazóis e de oxadiazóis, o respectivo preparo e a respectiva aplicação em terapêutica
FR2941457A1 (fr) * 2009-01-28 2010-07-30 Sanofi Aventis Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique
CN101863852B (zh) * 2010-06-29 2011-09-21 沈阳航空航天大学 含1,3,4-噁二唑杂环结构芳香二元胺及其制备方法
WO2012009698A1 (en) 2010-07-16 2012-01-19 Abbott Laboratories Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
NZ705225A (en) 2010-07-16 2016-11-25 Abbvie Bahamas Ltd Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
CN103554043B (zh) * 2013-09-03 2015-04-01 浙江医药高等专科学校 苯基取代的三唑酰胺类化合物及用途
CN103467398B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 三唑酰胺类化合物、其制备方法和其抗糖尿病用途
CN103483281B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 一类三唑酰胺类化合物、其制备方法和其抗糖尿病用途
CN103467406B (zh) * 2013-09-03 2014-12-17 浙江医药高等专科学校 卤素取代的四氮唑羧酸类化合物、其制备方法和用途
CN103467399B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 三唑酰胺类化合物、其制备方法和其用途
CN103467405B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 一类四氮唑羧酸类化合物、其制备方法和用途
CN103483282B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 苯基取代的三唑酰胺类化合物及用途
CN103467409B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 取代的四氮唑羧酸类化合物及其用途
CN103467407B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 四氮唑羧酸类化合物及其用途
CN103467408B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 一类四氮唑羧酸类化合物及其用途
JP2015131783A (ja) * 2014-01-14 2015-07-23 株式会社日本ファインケム アリール−１，２，４−トリアゾール誘導体の製造方法
CN106632125A (zh) * 2016-10-08 2017-05-10 李纪焕 一种烷基芳基取代噁二唑化合物的三组分合成方法
KR102720054B1 (ko) * 2017-03-30 2024-10-22 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637672A (en) 1968-07-09 1972-01-25 Osaka Seika Kogyo Kk Azole compounds
DE4031158A1 (de) 1990-04-21 1991-10-24 Bayer Ag Aryloxycarbonylverbindungen
JPH05202038A (ja) 1992-01-30 1993-08-10 Sumitomo Chem Co Ltd アゾール誘導体、その製造法およびそれを有効成分とする除草剤
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
GB0029974D0 (en) 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
US7507832B2 (en) 2009-03-24
US20070112045A1 (en) 2007-05-17
CN1909902A (zh) 2007-02-07
WO2005065683A1 (en) 2005-07-21
CA2549385A1 (en) 2005-07-21
EP1725231A1 (en) 2006-11-29
JP2007515484A (ja) 2007-06-14
AU2004311909A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
BRPI0410037B8 (pt) inibidores de fosfatidilinositol 3-cinase, sua composição farmacêutica, e seu uso
BRPI0908353B8 (pt) composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
BRPI0619255A8 (pt) Composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
BRPI0407097A (pt) Antagonista do casr
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
BRPI0408240A (pt) composto, utilização de um composto e composição farmacêutica
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BRPI0310032B8 (pt) derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BR9814055A (pt) Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.